Variants of SCARB1 and VDR involved in complex genetic interactions may be implicated in the genetic susceptibility to clear cell renal cell carcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Pos̈piech, Ewelina ^a   Ligęza, Janusz ^a   Wilk, Wacław ^b   Gołas, Aniela ^a   Jaszczyński, Janusz ^b   Stelmach, Andrzej ^b   Rys̈, Janusz ^b   Blecharczyk, Aleksandra ^a   Wojas Pelc, Anna ^c   Jura, Jolanta ^a   Branicki, Wojciech ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIRC5 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GNAS1 GENE; HAPLOTYPE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; META ANALYSIS (TOPIC); MULTIFACTOR DIMENSIONALITY REDUCTION; PHYLOGENETIC TREE; SCARB1 GENE; VDR GENE; BIOLOGICAL MODEL; CLINICAL TRIAL; EPISTASIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; KIDNEY TUMOR;

CALCITRIOL RECEPTOR; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; TUMOR PROTEIN; VDR PROTEIN, HUMAN;

CARCINOMA, RENAL CELL; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MALE; MODELS, GENETIC; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; SCAVENGER RECEPTORS, CLASS B;

EID: 84928550340     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/860405     Document Type: Article

References (79)

1. S. Storkel, J. N. Eble, K. Adlakha et al. , "Classification of renal cell carcinoma:workgroup no. 1. Union InternationaleContre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC), " Cancer, vol. 80, no. 5, pp. 987-989, 1997.
2. E. Maubec, V. Chaudru, H. Mohamdi et al. , "Characteristics of the coexistence of melanoma and renal cell carcinoma, " Cancer, vol. 116, no. 24, pp. 5716-5724, 2010.
3. M. C. Yu, T. M. Mack, R. Hanisch, C. Cicioni, and B. E. Henderson, "Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma, " Journal of the National Cancer Institute, vol. 77, no. 2, pp. 351-356, 1986.
4. W.-H. Chow, G. Gridley, J. F. Fraumeni, and B. Järvholm, "Obesity, hypertension, and the risk of kidney cancer in men, " The New England Journal ofMedicine, vol. 343, no. 18, pp. 1305-1311, 2000.
5. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al. , "Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, " European Journal of Cancer, vol. 49, no. 6, pp. 1374-1403, 2013.
6. M. P. Purdue, M. Johansson, D. Zelenika et al. , "Genomewide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13. 3, " Nature Genetics, vol. 43, no. 1, pp. 60-65, 2011.
7. J. P. T. Higgins, R. Shinghal, H. Gill et al. , "Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray, " The American Journal of Pathology, vol. 162, no. 3, pp. 925-932, 2003.
8. S. S. Han, M. Yeager, L. E. Moore et al. , "The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma, " Human Molecular Genetics, vol. 21, no. 5, pp. 1190-1200, 2012.
9. X. Wu, G. Scelo, M. P. Purdue et al. , "Agenome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11. 23, " HumanMolecular Genetics, vol. 21, no. 2, pp. 456-462, 2012.
10. M. Henrion, M. Frampton, G. Scelo et al. , "Common variation at 2q22. 3 (ZEB2) influences the risk of renal cancer, " Human Molecular Genetics, vol. 22, no. 4, pp. 825-831, 2013.
11. M. P. Purdue, Y. Ye, Z. Wang et al. , "A genome-wide association study of renal cell carcinoma among African Americans, " Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 1, pp. 209-214, 2013.
12. U. H. Frey, G. Lümmen, T. Jäger et al. , "The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma, " Clinical Cancer Research, vol. 12, no. 3, pp. 759-763, 2006.
13. S. Karami, P. Brennan, P. S. Rosenberg et al. , "Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk, " PLoS ONE, vol. 4, no. 9, Article ID e7013, 2009.
14. F. Bruyère, C. M. Hovens, M.-N. Marson et al. , "VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma, " The Journal of Urology, vol. 184, no. 4, pp. 1273-1278, 2010.
15. C. Qin, Q. Cao, P. Li et al. , "Functional promoter-31GCvariant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population, " PLoS ONE, vol. 7, no. 1, Article ID e28829, 2012.
16. W. Wang, X. Pan, X. Huo et al. , "A functional polymorphism C-1310G in the promoter region of Ku70/XRCC6 is associated with risk of renal cell carcinoma, "Molecular Carcinogenesis, vol. 51, supplement 1, pp. E183-E190, 2012.
17. M. De Martino, A. Haitel, G. Schatzl, H. C. Klingler, and T. Klatte, "The CASP8-652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis, " The Journal of Urology, vol. 190, no. 2, pp. 717-722, 2013.
18. K. Matsushita, O. Takeuchi, D. M. Standley et al. , "Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay, " Nature, vol. 458, no. 7242, pp. 1185-1190, 2009.
19. D. Mizgalska, P. Wgrzyn, K. Murzyn et al. , "Interleukin-1-inducibleMCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1 mRNA, " The FEBS Journal, vol. 276, no. 24, pp. 7386-7399, 2009.
20. L. Skalniak, D. Mizgalska, A. Zarebski, P. Wyrzykowska, A. Koj, and J. Jura, "Regulatory feedback loop between NF-B and MCP-1-induced protein 1 RNase, " The FEBS Journal, vol. 276, no. 20, pp. 5892-5905, 2009.
21. J. Liang, Y. Saad, T. Lei et al. , "MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NFkappaB signaling, " Journal of Experimental Medicine, vol. 207, no. 13, pp. 2959-2973, 2010.
22. E. Póspiech, J. Draus-Barini, T. Kupiec, A. Wojas-Pelc, and W. Branicki, "Gene-gene interactions contribute to eye colour variation in humans, " Journal of Human Genetics, vol. 56, no. 6, pp. 447-455, 2011.
23. E. Póspiech, A. Wojas-Pelc, S. Walsh et al. , "The common occurrence of epistasis in the determination of human pigmentation and its impact on DNA-based pigmentation phenotype prediction, " Forensic Science International: Genetics, vol. 11, no. 1, pp. 64-72, 2014.
24. E. Healy, S. A. Jordan, P. S. Budd, R. Suffolk, J. L. Rees, and I. J. Jackson, "Functional variation of MC1R alleles from redhaired individuals, " Human Molecular Genetics, vol. 10, no. 21, pp. 2397-2402, 2001.
25. S. Nejentsev, L. Godfrey, H. Snook et al. , "Comparative highresolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene, " Human Molecular Genetics, vol. 13, no. 15, pp. 1633-1639, 2004.
26. A. Dempfle, S. A. Wudy, K. Saar et al. , "Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies, " Human Molecular Genetics, vol. 15, no. 18, pp. 2772-2783, 2006.
27. R. A. Sturm, D. L. Duffy, N. F. Box et al. , "The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes, " Pigment Cell Research, vol. 16, no. 3, pp. 266-272, 2003.
28. M. D. Ritchie, L. W. Hahn, N. Roodi et al. , "Multifactordimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer, " The American Journal of Human Genetics, vol. 69, no. 1, pp. 138-147, 2001.
29. A. Jakulin and I. Bratko, "Analyzing attribute dependencies, " in Knowledge Discovery in Databases: PKDD 2003, vol. 2838 of Lecture Notes in Computer Science, pp. 229-240, 2003.
30. E. Kontopantelis and D. Reeves, "MetaEasy: a meta-analysis add-in for Microsoft Excel, " Journal of Statistical Software, vol. 30, no. 7, pp. 1-25, 2009.
31. D. G. Altman and J. M. Bland, "How to obtain the confidence interval from a P value, " BritishMedical Journal, vol. 343, Article ID d2090, 2011.
32. D. L. Williams, R. E. Temel, and M. A. Connelly, "Roles of scavenger receptor BI and apo A-I in selective uptake of HDL cholesterol by adrenal cells, " Endocrine Research, vol. 26, no. 4, pp. 639-651, 2000.
33. W.-J. Shen, J. Hu, Z. Hu, F. B. Kraemer, and S. Azhar, "Scavenger receptor class B type I (SR-BI): a versatile receptor withmultiple functions and actions, " Metabolism: Clinical and Experimental, vol. 63, no. 7, pp. 875-886, 2014.
34. C. Danilo, J. L. Gutierrez-Pajares, M. A. Mainieri, I. Mercier, M. P. Lisanti, and P. G. Frank, "Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development, " Breast Cancer Research, vol. 15, no. 5, article R87, 2013.
35. Q. Cao, C. Qin, X. Ju et al. , "Chromosome 11q13. 3 variantmodifies renal cell cancer risk in a Chinese population, " Mutagenesis, vol. 27, no. 3, pp. 345-350, 2012.
36. T. Su, Y. Han, Y. Yu et al. , "A GWAS-identified susceptibility locus on chromosome 11q13. 3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma, " Oncology Letters, vol. 6, no. 2, pp. 421-426, 2013.
37. K. Colston, M. J. Colston, and D. Feldman, "1, 25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture, " Endocrinology, vol. 108, no. 3, pp. 1083-1088, 1981.
38. S. R. T. Evans, A. M. Houghton, L. Schumaker et al. , "VitaminD receptor and growth inhibition by 1, 25-dihydroxyvitamin D3 in human malignant melanoma cell lines, "The Journal of Surgical Research, vol. 61, no. 1, pp. 127-133, 1996.
39. T. Okamoto, T. Fujioka, and S. Horiuchi, "A study of the metabolism of vitamin D in patients with renal cell carcinoma. With special reference to serum concentration of 1, 25-(OH)2D and its clinicla significance, " The Japanese Journal of Urology, vol. 82, no. 6, pp. 890-899, 1991.
40. T. Fujioka, Y. Suzuki, T. Okamoto, N. Mastushita, M. Hasegawa, and S. Omori, "Prevention of renal cell carcinoma by active vitamin D3, " World Journal of Surgery, vol. 24, no. 10, pp. 1205-1210, 2000.
41. C. Carlberg, S. Seuter, and S. Heikkinen, "The first genomewide viewof vitaminDreceptor locations and their mechanistic implications, " Anticancer Research, vol. 32, no. 1, pp. 271-282, 2012.
42. K. Köstner, N. Denzer, C. S. L. Müller, R. Klein, W. Tilgen, and J. Reichrath, "The relevance of vitamin D Receptor (VDR) gene polymorphisms for cancer: a review of the literature, " Anticancer Research, vol. 29, no. 9, pp. 3511-3536, 2009.
43. D. Bretherton-Watt, R. Given-Wilson, J. L. Mansi, V. Thomas, N. Carter, and K. W. Colston, "Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population, " British Journal of Cancer, vol. 85, no. 2, pp. 171-175, 2001.
44. H. S. Kim, P. A. Newcomb, C. M. Ulrich et al. , "Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium, " Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 8, pp. 869-874, 2001.
45. G. Lurie, L. R. Wilkens, P. J. Thompson et al. , "Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk, " Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2566-2571, 2007.
46. A. Kosiniak-Kamysz, A. Marczakiewicz-Lustig, M. Marcínska et al. , "Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects, " Melanoma Research, vol. 24, no. 4, pp. 388-396, 2014.
47. B. Toptaş, A. M. Kafadar, C. Cacina et al. , "The vitamin D receptor (VDR) gene polymorphisms in Turkish brain cancer patients, " BioMed Research International, vol. 2013, Article ID 295791, 6 pages, 2013.
48. M. I. Khan, Z. F. Bielecka, M. Z. Najm et al. , "Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (Review), " International Journal of Oncology, vol. 44, no. 2, pp. 349-363, 2014.
49. S. Gandini, P. Gnagnarella, D. Serrano et al. , "Vitamin D receptor polymorphisms and cancer, " Advances in Experimental Medicine and Biology, vol. 810, pp. 69-105, 2014.
50. T. Ikuyama, T. Hamasaki, H. Inatomi, T. Katoh, T. Muratani, and T. Matsumoto, "Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese, " Endocrine Journal, vol. 49, no. 4, pp. 433-438, 2002.
51. W. Obara, Y. Suzuki, K. Kato, S. Tanji, R. Konda, and T. Fujioka, "Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population, " International Journal of Urology, vol. 14, no. 6, pp. 483-487, 2007.
52. C. Ou, H. L. Zhao, B. Zhu, L. S. Huang, P. Z. Li, and M. Lao, "Association of vitamin D receptor gene polymorphism with the risk of renal cell carcinoma: a meta-analysis, " Journal of Receptors and Signal Transduction, vol. 34, no. 6, pp. 463-468, 2014.
53. F. Meng, P. Ma, C. Sui et al. , "The association between VDR polymorphisms and renal cell carcinoma susceptibility: a metaanalysis, " Tumor Biology, vol. 35, no. 6, pp. 6065-6072, 2014.
54. N. A. Morrison, J. C. Qi, A. Tokita et al. , "Prediction of bone density fromvitaminDreceptor alleles, " Nature, vol. 20, no. 367, pp. 284-287, 1994.
55. R. Moonesinghe, M. J. Khoury, T. Liu, and J. P. A. Ioannidis, "Required sample size and nonreplicability thresholds for heterogeneous genetic associations, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 617-622, 2008.
56. J. H. Moore, "The ubiquitous nature of epistasis in determining susceptibility to common human diseases, " Human Heredity, vol. 56, no. 1-3, pp. 73-82, 2003.
57. L. W. Hahn, M. D. Ritchie, and J. H. Moore, "Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions, " Bioinformatics, vol. 19, no. 3, pp. 376-382, 2003.
58. A. Lania and A. Spada, "G-protein and signalling in pituitary tumours, " Hormone Research, vol. 71, supplement 2, pp. 95-100, 2009.
59. U. H. Frey, A. Eisenhardt, G. Lümmen et al. , "The T393C polymorphism of the Gs gene (GNAS1) is a novel prognostic marker in bladder cancer, " Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 871-877, 2005.
60. W. Arjumand, S. T. Ahmad, S. Nafees et al. , "GNAS1 (Gs) gene T393C polymorphism and renal cell carcinoma risk in a north Indian population: a case-control study, " Genetic Testing and Molecular Biomarkers, vol. 16, no. 9, pp. 1062-1066, 2012.
61. G. Kapellos, K. Polonifi, D. Farmakis et al. , "Overexpression of Survivin levels in circulation and tissue samples of lung cancer patients, " Anticancer Research, vol. 33, no. 8, pp. 3475-3480, 2013.
62. J. Song, H. Su, Y.-Y. Zhou, and L.-L. Guo, "Prognostic value of survivin expression in breast cancer patients: a meta-analysis, " Tumor Biology, vol. 34, no. 4, pp. 2053-2062, 2013.
63. Y. Lei, Z. Geng, W. Guo-Jun, W. He, and Y. Jian-Lin, "Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance, " Molecular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 23-31, 2010.
64. J. S. Jang, K. M. Kim, K. H. Kang et al. , "Polymorphisms in the survivin gene and the risk of lung cancer, " Lung Cancer, vol. 60, no. 1, pp. 31-39, 2008.
65. A. M. F. Liu, R. K. H. Lo, C. S. S. Wong, C. Morris, H. Wise, and Y. H. Wong, "Activation of STAT3 by G distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase, " The Journal of Biological Chemistry, vol. 281, no. 47, pp. 35812-35825, 2006.
66. Y. Aoki, G. M. Feldman, and G. Tosato, "Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma, " Blood, vol. 101, no. 4, pp. 1535-1542, 2003.
67. W. Yang, K. Yoshigoe, X. Qin et al. , "Identification of genes and pathways involved in kidney renal clear cell carcinoma, " BMC Bioinformatics, vol. 15, supplement 17, article S2, 2014.
68. S.-I. Miura, M. Fujino, Y. Matsuo et al. , "High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 802-808, 2003.
69. M. Zamanian-Daryoush, D. Lindner, T. C. Tallant et al. , "The cardioprotective protein apolipoprotein a1 promotes potent anti-tumorigenic effects, "The Journal of Biological Chemistry, vol. 288, no. 29, pp. 21237-21252, 2013.
70. V. H. Haase, "The VHL tumor suppressor: master regulator of HIF, " Current Pharmaceutical Design, vol. 15, no. 33, pp. 3895-3903, 2009.
71. X. Na, H. O. Duan, E. M. Messing et al. , "Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein, " The EMBO Journal, vol. 22, no. 16, pp. 4249-4259, 2003.
72. B. I. Rini and E. J. Small, "Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, " Journal of ClinicalOncology, vol. 23, no. 5, pp. 1028-1043, 2005.
73. U. Brudnik, W. Branicki, A. Wojas-Pelc, and P. Kanas, "The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818AG polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population, " Experimental Dermatology, vol. 18, no. 2, pp. 167-174, 2009.
74. D. L. Duffy, Z. Z. Zhao, R. A. Sturm, N. K. Hayward, N. G. Martin, and G. W. Montgomery, "Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma, " The Journal of Investigative Dermatology, vol. 130, no. 2, pp. 520-528, 2010.
75. C. Beisland, O. Talleraas, A. Bakke, and J. Norstein, "Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study, " BJU International, vol. 97, no. 4, pp. 698-702, 2006.
76. P. T. Bradford, D. M. Freedman, A. M. Goldstein, and M. A. Tucker, "Increased risk of second primary cancers after a diagnosis of melanoma, " Archives of Dermatology, vol. 146, no. 3, pp. 265-272, 2010.
77. C. Bertolotto, F. Lesueur, S. Giuliano et al. , "A SUMOylationdefective MITF germline mutation predisposes to melanoma and renal carcinoma, " Nature, vol. 480, no. 7375, pp. 94-98, 2011.
78. A. Lindskog, K. Ebefors, M. E. Johansson et al. , "Melanocortin 1 receptor agonists reduce proteinuria, " Journal of theAmerican Society of Nephrology, vol. 21, no. 8, pp. 1290-1298, 2010.
79. Z. Hochberg and A. R. Templeton, "Evolutionary perspective in skin color, vitamin D and its receptor, " Hormones, vol. 9, no. 4, pp. 307-311, 2010.